Linperlisib with CPT for relapsed or refractory non-Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lymphoma called FL, PTCL, NK/T-cell lymphoma, CLL, MZL, or MCL that has come back or not responded to prior therapy.
- You have at least one measurable tumor or sign of disease (like an enlarged lymph node or high lymphocyte count).
- You have received at least one or two prior treatments depending on your lymphoma type and it stopped working or wasn't effective enough.
- You are in generally good health (able to do daily activities, with adequate organ function).
- You are willing to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests a combination of two drugs, linperlisib and chidamide, for people whose peripheral T-cell lymphoma has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.